Abstract
Numerous studies have investigated the potential use of TNF-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic since its discovery in 1995 – because TRAIL is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. Consequently, a great deal is known about TRAIL/TRAIL receptor expression, the molecular components of TRAIL receptor signaling, and methods of altering tumor cell sensitivity to TRAIL-induced apoptosis. Our laboratory was the first to report the possibility of TRAIL gene transfer therapy as an alternative method of using TRAIL as an antitumor therapy. As with recombinant proteins administered systemically, intratumoral TRAIL gene delivery also has limitations that can restrict its full potential. Translating the preclinical TRAIL studies into the clinic has started, with the hope that TRAIL will exhibit robust tumoricidal activity against human primary tumors in situ with minimal toxic side effects.
Keywords: TRAIL, apoptosis, tumor, adenovirus, immunotherapy
Current Gene Therapy
Title: TRAIL Gene Therapy: From Preclinical Development to Clinical Application
Volume: 9 Issue: 1
Author(s): Thomas S. Griffith, Brittany Stokes, Tamara A. Kucaba, James K. Earel Jr., Rebecca L. VanOosten, Erik L. Brincks and Lyse A. Norian
Affiliation:
Keywords: TRAIL, apoptosis, tumor, adenovirus, immunotherapy
Abstract: Numerous studies have investigated the potential use of TNF-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic since its discovery in 1995 – because TRAIL is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. Consequently, a great deal is known about TRAIL/TRAIL receptor expression, the molecular components of TRAIL receptor signaling, and methods of altering tumor cell sensitivity to TRAIL-induced apoptosis. Our laboratory was the first to report the possibility of TRAIL gene transfer therapy as an alternative method of using TRAIL as an antitumor therapy. As with recombinant proteins administered systemically, intratumoral TRAIL gene delivery also has limitations that can restrict its full potential. Translating the preclinical TRAIL studies into the clinic has started, with the hope that TRAIL will exhibit robust tumoricidal activity against human primary tumors in situ with minimal toxic side effects.
Export Options
About this article
Cite this article as:
Griffith S. Thomas, Stokes Brittany, Kucaba A. Tamara, Earel Jr. K. James, VanOosten L. Rebecca, Brincks L. Erik and Norian A. Lyse, TRAIL Gene Therapy: From Preclinical Development to Clinical Application, Current Gene Therapy 2009; 9 (1) . https://dx.doi.org/10.2174/156652309787354612
DOI https://dx.doi.org/10.2174/156652309787354612 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Carbon Monoxide in Kidney Function: Is a little Carbon Monoxide Good for the Kidney?
Current Pharmaceutical Biotechnology Cytotoxic Effect of the Red Beetroot (Beta vulgaris L.) Extract Compared to Doxorubicin (Adriamycin) in the Human Prostate (PC-3) and Breast (MCF-7) Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Revising Skin Cancers by Means of Epigenetic Markers
Recent Patents on Biomarkers Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field
Current Gene Therapy Drug Metabolism and Pharmacokinetics of Nanodrugs from Chinese Medicines and Natural Products
Current Drug Metabolism Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA Hypoxia PET Tracers in EBRT Dose Planning in Head and Neck Cancer
Current Radiopharmaceuticals Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Epigenome-Wide Association Studies (EWAS) in Cancer
Current Genomics Structural Basis of Resistance to Anti-Cytochrome bc<sub>1</sub> Complex Inhibitors: Implication for Drug Improvement
Current Pharmaceutical Design Light Directed Gene Transfer by Photochemical Internalisation
Current Gene Therapy Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses
Current Cancer Drug Targets Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms
Current Pharmaceutical Design Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
Current Medicinal Chemistry Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics